Yamamoto R, Jensen Mk, Aroner S, et al. - Researchers sought to examine the prospective relationships between HDL subspecies containing and lacking apoC-III at baseline and insulin sensitivity at year 3. The sample consisted of 864 healthy volunteers recruited from the RISC study, a multi-center European clinical trial that began recruiting participants in 2002 and lasted for 3 years. Both HDL containing apoC-III and apoC-III in HDL have a negative effect on HDL's beneficial properties on insulin response to glucose. The findings point to HDL-associated apoC-III as a promising target for diabetes prevention and treatment.